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non-gastroenterology (10471; 50.1%) and gastroenterology specialists were similar,
but monthly trend of gastroenterology visits significantly increased (p0.001) in
different tiers of medical facilities. Antispasmodics (13904; 41.0%) and laxatives
(9240; 27.2%) were the most frequently prescribed and monthly consumptions of
antipropulsive, antispasmodics and propulsive significantly increased (p0.001)
over time. CONCLUSIONS: A small cohort of outpatients receiving long-term IBS
treatments contributed to 20% of all IBS outpatient expenditure. As their medical
utilization and cost are substantially increasing, further economic evaluation is
needed to inform resource allocation decisions in the future.
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OBJECTIVES: To examine the influence of 5-ASA adherence rates on total annual
direct costs in UC patients using a budget impact model. METHODS: This model
assessed health care costs and utilization (US payer’s perspective, 1-year horizon)
in patients 18 years with newly diagnosed or relapsing mild-to-moderate UC
taking one of the following treatments: Colazal®, Pentasa®, Asacol®, or Lialda®/
Mezavant®. The default health plan share (model base case) was based on the
average market share of 5-ASA formulations from June 2009 to May 2010. Adher-
ence rates andmean days of therapy were based on published claims data; relapse
rates were calculated for adherent patients (having a medication possession ratio
[MPR] 0.8) and nonadherent patients (MPR 0.8). All-cause direct costs were ob-
tained from published literature and converted to 2010 US dollars using the Con-
sumer Price Index. RESULTS: Total annual cost of care for patients on Lialda/Meza-
vant ($12,771) was the lowest of the 5-ASA therapies: Asacol, $13,098; Colazal,
$13,423; Pentasa, $14,139. Patients on Lialda/Mezavant also had the lowest inpa-
tient, emergency room, and office visit expenses. Although pharmacy costs were
higher for Lialda/Mezavant ($2801) compared with Asacol ($2669; the lowest phar-
macy cost of examined 5-ASAs), this incremental cost increase was offset by the
lower costs of hospital care for Lialda/Mezavant patients. Assuming a UC preva-
lence of 0.23%, a health plan with 1 million participants could save $419,565 if all
patients on Asacol switched to Lialda/Mezavant. Results of sensitivity analyses
revealed that Lialda/Mezavant adherence rate and inpatient costs for nonadherent
patients were the most influential variables impacting total annual health plan
cost savings. CONCLUSIONS: Lower inpatient health care costs were primarily
driven by decreases in relapse frequency associated with higher treatment adher-
ence rates. Therefore, optimal savings for health plansmay result from inclusion of
medications on formularies based on therapeutic value (including improved ad-
herence) rather than pharmacy costs.
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OBJECTIVES: A cost-effectiveness analysis on two vaccination programs against
rotavirus in Guangzhou, Chinawas conducted for two purposes: 1) a test case in the
context of urban areas to enrich the knowledge of national health policymakers in
determining the inclusion of these vaccination programs in the Chinese Expanded
Programme on Immunization, and 2) the findings may inform the city authorities
to include the vaccines in local immunization plans.METHODS: The two interven-
tions under evaluation (through the incremental cost-effectiveness ratio [ICER]) are
Lanzhou lamb vaccine and Rotarix. Major costs include those associated with vac-
cination (prices of vaccines, program costs of implementation, and vaccine wast-
age) and associated with diarrhea (direct medical costs: outpatient visit and hos-
pitalization; indirect costs: transportation and parents’ loss of wage). Effects were
assessed in terms of the number of deaths averted and the number of disability
adjusted life years (DALYs) averted. Epidemiological and other parameters are also
included. Additionally, 1- and 2-way sensitivity analyses were performed to assess
the uncertainty of the base case analysis. RESULTS: The ICER of the Lanzhou lamb
vaccine is more than $135,000 per death averted and $4146.16 per DALY averted;
the ICER of Rotarix is more than $1.2 million per death averted and $36807.29 per
DALY averted. Uncertainty analyses indicate that disease prevalence and the price
and efficacy of Rotarix are most influential in determining ICERs. Cost-effective-
ness with respect to these leading influential factors was evaluated.
CONCLUSIONS: In terms of DALYs averted with respect to the per capita GDP, the
Lanzhou lamb vaccine is very cost-effective (ICER  per capita GDP) and Rotarix
cost-effective (ICER  3 times per capita GDP). Two-way sensitivity analyses may
also suggest potential competitive pricing strategy for Rotarix in terms of cost-
effectiveness. Limitations and generalizability of this study are discussed along
with directions for future research.
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OBJECTIVES: This article presents the methodology and results of the phar-
macoeconomic analysis of the MagnexMetronidazole against the combination
therapies CefuroximeMetronidazole and CeftriaxoneMetronidazoleAmi-
kacin in the treatment of Gastrointestinal surgeries. METHODS: This prospec-
tive study was conducted at a tertiary care teaching hospital in India on subjects
randomly, MagnexMetronidazole was compared with the combination of two
groups CefuroximeMetronidazole or CeftriaxoneMetronidazoleAmikacin.
Pharmacoeconomic analysis was the primary objective and the study was con-
ducted in the successfully treated patients. All comparisons between treatment
groups were conducted using Analysis of Variance (ANOVA). All costs were
reported as Indian Rupee(INR) and actual unit costs collected in 2011 were use
for the analyses. [1 USD 49 INR]. RESULTS: In the successfully treated patients,
the average cost of treatment was numerically lower in the CeftriaxoneMet-
ronidazoleAmikacin combination. The analyses found that the average cost of
treatment for CeftriaxoneMetronidazoleAmikacin was INR 2989.86, Cefu-
roximeMetronidazole was INR 4191.92 and MagnexMetronidazole was INR
4458.04. Average cost per day for MagnexMetronidazole was INR 800.36,
CefuroximeMetronidazole was INR 744.42 and for CeftriaxoneMetro-
nidazoleAmikacin was INR 536.77. The Incremental Cost Effectiveness Ratio
between MagnexMetronidazole and CefuroximeMetronidazole was 5.37 and
between MagnexMetronidazole and CeftriaxoneMetronidazoleAmikacin
was 5.49. CONCLUSIONS: Prospective study was conducted in the teaching hos-
pital and average cost of treatment was the primary objective of the study. The
analyses found that average cost for MagnexMetronidazole was INR 4458.04,
CefuroximeMetronidazole was INR 4191.92 and CeftriaxoneMetronidazole
Amikacin was INR 2989.86. Average difference in cost between Magnex
Metronidazole and CefuroximeMetronidazole was 6.1% and between Mag-
nexMetronidazole and CeftriaxoneMetronidazole Amikacin was 49%.
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OBJECTIVES: To assess adherence to various oral formulations of 5-ASA for the
treatment of UC in a UK patient population.METHODS: Dispensed drug data from
10 million UK patients were examined in a retrospective analysis of adherence to
oral 5-ASA therapy. Patients receiving 2 dispensed prescriptions of 5-ASA be-
tween January 2008 andDecember 2009were eligible; thosemissing age and gender
data were excluded. Patients with a medication possession ratio (MPR) 90% were
considered adherent. Patients were grouped by 5-ASA formulation and dose; age-
and gender-adjusted adherence rates were calculated and compared using chi-
square, 1-sample t-tests, and odds ratio (OR) statistics. RESULTS: A total of 11,608
patients met inclusion criteria. Mean (SD) age was 51.7 (18.1) years, with an even
gender distribution. Overall, 30.9% of patients were adherent. More patients were
adherent to Mezavant (48.3%) compared with any other formulation: Asacol 800
mg, 40.7%; Mesren 400 mg, 36.7%; Pentasa 1,000 mg, 31.8%; Pentasa 500 mg, 29.7%;
Asacol 400 mg, 29.6%; Colazide 750 mg, 27.8% (all comparisons P 0.001). Mean
continuous adherence rates (MPR acrossmultiple refills), adjusted for age and gen-
der, were also higher for Mezavant (87%) compared with the other 5-ASAs: Asacol
800 mg, 82%; Pentasa 1,000 mg, 75%; Mesren 400 mg, 74%; Pentasa 500 mg, 69%;
Colazide 750 mg, 68%; and Asacol 400 mg, 66% (P 0.001 vs. other 5-ASAs). ORs for
likelihood of adherence revealed that, compared with Mezavant, patients on any
other 5-ASA were less likely to be adherent: Asacol 800 mg, 0.69; Pentasa 1,000 mg,
0.49; Mesren 400 mg, 0.47; Pentasa 500 mg, 0.42; Colazide 750 mg, 0.36; and Asacol
400 mg, 0.36 (all comparisons P 0.05). CONCLUSIONS: Overall adherence with
5-ASA therapies was low. Patients on once-daily Mezavant demonstrated greater
adherence compared with those on other 5-ASA formulations.
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OBJECTIVES: To assess adherence and persistence to oral mesalamine treatment
for UC using the Quebec provincial public health plan (RAMQ) database, and iden-
tify patient characteristics associated with adherence and persistence.METHODS:
A retrospective prescription claims analysis was conducted on a random sampling
of patients with UC from the RAMQ database. Eligible patients initiated mesala-
mine therapy between January 2005 and December 2009, and could not have a
diagnosis of Crohn’s disease. Adherence and persistence weremeasured for 1 year
after the index prescription; adherent patients were defined as having a medica-
tion possession ratio 0.8 and persistent patients had a subsequent claim for me-
salamine within 60 days of the prior claim. Odds of adherence and persistence
based upon patient characteristics (eg, gender, age, corticosteroid use, comorbidi-
ties) were modeled with logistic regression. RESULTS: Of 12,765 sampled database
patients, 1,681 met the inclusion criteria. Mean (SD) age was 55.3 (17.8) years and
43.4% were male; the most common comorbidities were hypertension (50.1%),
heart disease (41.3%), respiratory illness (33.9%) anddiabetes (32.7%). Overall, 27.7%
of patients were adherent at 12 months; 45.5% of patients were persistent at 12
months, a decrease from 66.7% at 3 months. Male gender and current use of corti-
costeroids were associated with higher adherence (odds ratio [OR] [95% confidence
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